A388870 Stock Overview
Develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pharos iBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,260.00 |
| 52 Week High | ₩21,250.00 |
| 52 Week Low | ₩7,850.00 |
| Beta | 0 |
| 11 Month Change | -17.73% |
| 3 Month Change | -16.73% |
| 1 Year Change | -33.28% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -5.38% |
Recent News & Updates
Shareholder Returns
| A388870 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | -8.1% | 2.9% |
| 1Y | -33.3% | 18.1% | -2.8% |
Return vs Industry: A388870 underperformed the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A388870 underperformed the KR Market which returned -4% over the past year.
Price Volatility
| A388870 volatility | |
|---|---|
| A388870 Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A388870 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A388870's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 33 | n/a | www.pharosibio.com |
Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Pharos iBio Co., Ltd. Fundamentals Summary
| A388870 fundamental statistics | |
|---|---|
| Market cap | ₩106.71b |
| Earnings (TTM) | -₩10.49b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.2x
P/E RatioIs A388870 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A388870 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩22.75m |
| Gross Profit | -₩22.75m |
| Other Expenses | ₩10.47b |
| Earnings | -₩10.49b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -812.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A388870 perform over the long term?
See historical performance and comparison